Sally Smith Hughes, Genentech: The Beginnings of Biotech Within roughly five years, the pair succeeded in combining Cohen’s plasmids and Boyer’s enzymes to create recombinant DNA technology, ...

The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving insulin.

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

The slice of code — a stretch of DNA that acts like a dial to turn up the expression of certain genes — expanded the outer ...

Testimony resumes Monday. Ash Vallier told Read attorney David Yannetti that the items reconstructed were also previously tested for DNA. “Were you made aware that there were three contributors ...

PRINCETON, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ...

BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company ...

Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec” or "Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and ...

Elaine Chen covers biotech, co-writes The Readout newsletter ... a powerful technology for making precise changes to DNA. Harry Malech, an NIH researcher and investigator on the study, announced ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Developed by Biovet, a subsidiary of Bharat Biotech, BIOLUMPIVAXIN addresses a serious challenge the animal husbandry sector faces, offering a great relief to farmers. Lumpy skin disease (LSD ...

The biotech ended March with $624.3 million, an amount it forecast would fund operations through 2027 under its previous spending plan. Beyond belrestotug, iTeos is developing an ENT1 inhibitor ...